At a glance
ClinicalIndex Comparison RecordPhase 3Active· 516 enrolled
Drug / intervention
Baricitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Baricitinib, Placebo, and 1 other intervention for Atopic Dermatitis. Active but no longer recruiting, targeting 516 participants across 78 sites in 17 countries.
Detailed Summary
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesArgentina, Australia, Austria, Brazil, Czechia, France, Germany, Hungary, India, Israel, Japan, Mexico, Poland, Russia, Spain, Taiwan, United Kingdom
CollaboratorsIncyte Corporation
Timeline
Phase 3ActiveOverdue
2020202120222023202420252026
First PostedMay 2019
Enrollment StartMay 2019
Primary CompletionApr 2022
Study CompletionMay 2026
TodayJul 2026
First PostedMay 16, 2019
Enrollment StartMay 24, 2019
Primary CompletionApr 24, 2022
Study CompletionMay 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.1 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally
Topical corticosteroiddrug
Administered as standard-of-care